DK165667B - Injektionsoploesning indeholdende cholintheophyllinat - Google Patents
Injektionsoploesning indeholdende cholintheophyllinat Download PDFInfo
- Publication number
- DK165667B DK165667B DK394885A DK394885A DK165667B DK 165667 B DK165667 B DK 165667B DK 394885 A DK394885 A DK 394885A DK 394885 A DK394885 A DK 394885A DK 165667 B DK165667 B DK 165667B
- Authority
- DK
- Denmark
- Prior art keywords
- injection solution
- cholinetehyllinate
- acid
- solution containing
- weight
- Prior art date
Links
- 239000000243 solution Substances 0.000 title claims abstract description 12
- 238000002347 injection Methods 0.000 title claims abstract description 11
- 239000007924 injection Substances 0.000 title claims abstract description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 abstract description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Structures Of Non-Positive Displacement Pumps (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Beans For Foods Or Fodder (AREA)
Description
i
DK 165667 B
Den foreliggende opfindelse angår en vandig injektionsopløsning indeholdende cholintheophy11 i nat, der er ejendommelig ved det i kravets kendetegnende del angivne.
5 2-hydroxy-N,Ν,Ν-trimethylethanaminium-saltet af 3,7-dihydro-l,3-dimethyl-lH-purin-2,6-dion (1:1) (cholintheophyllinat) er kendt som værende et farmakologisk virksomt stof, der er indeholdt som aktivt stof i bronkolytisk virksomme lægemidler ("Rote Liste 1980" - Editio Cantor Verlag, Aulendorf, Wurttem-10 berg DT, nr. 27 042). Dette theophyllinsalt har i forhold til andre salte af dette stof, som f.eks. theophyllin-ethylen-diamin (=aminophyllin) det fortrin, at det bedre kan tåles. (Arzneim. Forsch., 31, 1981, 1503 ff og 32, 1982, 409 ff).
De cholintheophyllinatholdige præparater indgives oralt. Dette 15 har til følge at koncentrationen af det aktive stof i blodplasma først når sit maksimum efter ca. to timer (Brit. J. Pharmacol., 3, 1976, side 194 - 196), hvilket navnlig er en ulempe ved behandling af svære krampetilstande. Der foreligger således et behov for et injektionsmiddel, der indholder dette 20 aktive stof.
Vandige opløsninger af cholintheopyllinat er ikke stabile og er således uegnede som injektionsmidler. Dersom man forsøger at stabilisere disse opløsninger ved tilsætning af i den ga-25 leniske teknik konventionelt anvendte syrer eller antioxidanter (myresyre, eddikesyre, phosphorsyre, benzoesyre, glutarsyre, adipinsyre, sorbinsyre, æblesyre, vinsyre, ascorbinsyre, citronsyre etc.) udfældes cholintheophyllinat eller man opnår lige så ustabile opløsninger, der misfarves og ikke er steriliserbare. 30
Det har nu vist sig, at man opnår overraskende stabile vandige opløsninger af cholintheophyllinat, når man til denne opløsning, regnet på saltet, tilsætter 5 til 8, fortrinsvis 6 til 7, og navnlig 6,5 til 6,8 vægt% propionsyre. De vundne opløs-35 m'nger har en pH-værdi på 9 til 10 - fortrinsvis 9,4 til 9,8.
De kan på sædvanlig måde fyldes i ampuller eller lignende og steriliseres.
2
DK 165667B
I disse vandige injektionsopløsninger udgør koncentrationen af cholintheophyllinat 1 til 25, fortrinsvis 2 til 20, og navnlig 3 til 15 vægt%.
5 De vandige injektionsopløsninger ifølge opfindelsen anvendes blandt andet til behandling af akutte og svære krampetilstande i bronkialvejen ved kronisk bronkitis, lungeemfysem og bron-kialastma - navnlig ved status astmatikus. Den indgivne startdosis bør fortrinsvis udgøre 5 til 10 mg/kg, og navnlig 7 10 til 9 mg/kg legemsvægt, og den indgivne dagsdosis bør ligge inden for grænserne fra 15 til 40 mg/kg og navnlig inden for grænserne fra 19 til 31 mg/kg legemsvægt.
De efterfølgende eksempler tjener til illustration af den 15 vandige injektionsopløsning ifølge opfindelsen.
Eksempel 1
Man tilbereder ud fra 20 300.00 g cholintheophyllinat 20,00 g propionsyre og 9730.00 g redestilleret vand 25 10,00 liter injektionsopløsning, der sterilfiltreres og under sterile betingelser fyldes i ampuller med 10,00 ml pr. ampul.
Eksempel 2 30 Man tilbereder ud fra 150.00 g cholintheophyllinat 10.00 g propionsyre og 875.00 g redestilleret vand 35 1.00 liter injektionsopløsning, der sterilfiltreres og fyldes i ampuller med 1,00 ml pr. ampul.
Claims (1)
- DK 165667B o Pa tent k. rav Vandig injektionsopløsning, kendetegnet ved, at 5 den indeholder 1 til 25 vægt% 2-hydroxy-N,N,N-trimethylethan-aminium-salt af 3,7-dihydro-l,3-dimethyl-lH-purin-2,6-dion (1:1) og regnet i forhold til dette salt 5 til 8 vægt% propion-syre. 10 15 20 25 30 35
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3432112 | 1984-08-29 | ||
| DE19843432112 DE3432112A1 (de) | 1984-08-29 | 1984-08-29 | Injektionsloesung |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| DK394885D0 DK394885D0 (da) | 1985-08-29 |
| DK394885A DK394885A (da) | 1986-03-01 |
| DK165667B true DK165667B (da) | 1993-01-04 |
| DK165667C DK165667C (da) | 1993-06-14 |
Family
ID=6244406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK394885A DK165667C (da) | 1984-08-29 | 1985-08-29 | Injektionsoploesning indeholdende cholintheophyllinat |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4708957A (da) |
| EP (1) | EP0173240B1 (da) |
| JP (1) | JPS61126027A (da) |
| AT (1) | ATE49705T1 (da) |
| AU (1) | AU588242B2 (da) |
| CA (1) | CA1253078A (da) |
| DE (2) | DE3432112A1 (da) |
| DK (1) | DK165667C (da) |
| ES (1) | ES8608314A1 (da) |
| FI (1) | FI81005C (da) |
| GR (1) | GR852062B (da) |
| IE (1) | IE58387B1 (da) |
| IL (1) | IL76245A0 (da) |
| NO (1) | NO169274C (da) |
| PT (1) | PT81035B (da) |
| ZA (1) | ZA856625B (da) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE889747C (de) * | 1952-01-01 | 1953-09-14 | Knoll Ag | Verfahren zur Herstellung von waesserigen Losungen des Theophyllins |
| GB823242A (en) * | 1956-05-31 | 1959-11-11 | Warner Lambert Pharmaceutical | Therapeutic compositions containing choline salts of dialkyl xanthines |
| US3928609A (en) * | 1973-04-05 | 1975-12-23 | Dooner Lab | Non-alcoholic theophylline product |
| US3900474A (en) * | 1973-05-14 | 1975-08-19 | Kendall & Co | Trifluoroalkyl, fluorobenzyl, pentafluorobenzyl, fluorobenzenesulfonyl, and pentafluorobenzenesulfonyl theophyllines |
| CH619364A5 (da) * | 1976-04-02 | 1980-09-30 | Seebach Adolf Ag |
-
1984
- 1984-08-29 DE DE19843432112 patent/DE3432112A1/de not_active Withdrawn
-
1985
- 1985-08-02 AU AU45794/85A patent/AU588242B2/en not_active Ceased
- 1985-08-21 EP EP85110480A patent/EP0173240B1/de not_active Expired - Lifetime
- 1985-08-21 DE DE8585110480T patent/DE3575519D1/de not_active Expired - Fee Related
- 1985-08-21 AT AT85110480T patent/ATE49705T1/de not_active IP Right Cessation
- 1985-08-27 GR GR852062A patent/GR852062B/el unknown
- 1985-08-28 IE IE211485A patent/IE58387B1/en not_active IP Right Cessation
- 1985-08-28 CA CA000489536A patent/CA1253078A/en not_active Expired
- 1985-08-28 NO NO853386A patent/NO169274C/no unknown
- 1985-08-28 PT PT81035A patent/PT81035B/pt not_active IP Right Cessation
- 1985-08-29 JP JP60188743A patent/JPS61126027A/ja active Pending
- 1985-08-29 IL IL76245A patent/IL76245A0/xx not_active IP Right Cessation
- 1985-08-29 ES ES546511A patent/ES8608314A1/es not_active Expired
- 1985-08-29 US US06/770,449 patent/US4708957A/en not_active Expired - Fee Related
- 1985-08-29 ZA ZA856625A patent/ZA856625B/xx unknown
- 1985-08-29 FI FI853308A patent/FI81005C/fi not_active IP Right Cessation
- 1985-08-29 DK DK394885A patent/DK165667C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK165667C (da) | 1993-06-14 |
| DE3432112A1 (de) | 1986-03-13 |
| FI81005B (fi) | 1990-05-31 |
| ES8608314A1 (es) | 1986-07-16 |
| FI853308L (fi) | 1986-03-01 |
| PT81035B (pt) | 1987-11-11 |
| IE58387B1 (en) | 1993-09-08 |
| DE3575519D1 (de) | 1990-03-01 |
| IL76245A0 (en) | 1986-01-31 |
| EP0173240A3 (en) | 1987-06-24 |
| EP0173240B1 (de) | 1990-01-24 |
| EP0173240A2 (de) | 1986-03-05 |
| US4708957A (en) | 1987-11-24 |
| DK394885A (da) | 1986-03-01 |
| IE852114L (en) | 1986-02-28 |
| DK394885D0 (da) | 1985-08-29 |
| NO169274C (no) | 1992-06-03 |
| AU4579485A (en) | 1986-03-06 |
| PT81035A (de) | 1985-09-01 |
| JPS61126027A (ja) | 1986-06-13 |
| FI853308A0 (fi) | 1985-08-29 |
| GR852062B (da) | 1985-12-23 |
| ES546511A0 (es) | 1986-07-16 |
| AU588242B2 (en) | 1989-09-14 |
| NO169274B (no) | 1992-02-24 |
| NO853386L (no) | 1986-03-03 |
| ZA856625B (en) | 1986-04-30 |
| FI81005C (fi) | 1990-09-10 |
| ATE49705T1 (de) | 1990-02-15 |
| CA1253078A (en) | 1989-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4245192B2 (ja) | 3,000〜14,000ダルトンの平均分子量を有するpvpからなる組成物 | |
| US5589491A (en) | Injection and injection kit containing omeprazole and its analogs | |
| EP0799046B1 (en) | Stable solutions of 2-chloro-2'-deoxyadenosine | |
| NO176389B (no) | Fremgangsmåte ved fremstilling av vandig folinatlösning stabil ved kjöleskapstemperatur | |
| JPH0524135B2 (da) | ||
| KR20020022794A (ko) | 일반 염을 함유하는 목시플록사신 제형 | |
| EP0143478B1 (en) | Stable, aqueous, acidic solution of cis-platinum, suitable for injection | |
| DK174624B1 (da) | Sprøjteklare, vandige, alkaliske injektionsopløsninger af torasemid og fremgangsmåde til fremstilling deraf | |
| US5633240A (en) | Parenteral solutions containing metolazone | |
| US4789660A (en) | Insulin administration using methyl and propyl paraben | |
| EP1000079B1 (en) | New formulation | |
| CA1303992C (en) | Stable injectable solutions of vinca dimer salts | |
| JP3118258B2 (ja) | ジホスホン酸およびその塩を含有する医薬品 | |
| DK175485B1 (da) | Lægemidler indeholdende pentamidin | |
| EP0801571B1 (en) | Soluble 2-chloro-2'-deoxyadenosine formulations | |
| DK165667B (da) | Injektionsoploesning indeholdende cholintheophyllinat | |
| RU2219917C2 (ru) | Стабильные растворы митоксантрона | |
| GB2094142A (en) | Injectable solution containing theophylline and a basic amino acid | |
| US20040092587A1 (en) | Freeze-dried preparation of n[o-(p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing the same | |
| DE3586993T3 (de) | Kontinuierliche intravenöse infusion von adenosin an menschlichen patienten, einheitsdosierungsform von adenosin und dessen verwendung bei der herstellung von arzneimitteln. | |
| JP2004509921A (ja) | 酸含有量が少ない保存安定性のあるシプロフロキサシンの輸液 | |
| EP2965747A1 (en) | Dialysate acid precursor composition enriched with phosphorous | |
| CA2240266A1 (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
| ES2275648T3 (es) | Utilizacion de enoxaparina para el tratamiento de la isquemia cerebral. | |
| US2128851A (en) | Theophylline-piperazine preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |